Advancements in Cancer Immunotherapy
Shift from Traditional Enhancement Strategies
Historically, antitumor therapies have concentrated on boosting systemic immune activity. Researchers at Yale University have recently spotlighted a novel approach to cancer immunotherapy that promises more effective treatment options. Cancer research has primarily revolved around enhancement therapies designed to improve the immune system’s ability to activate T cells, which are crucial for identifying and destroying cancerous cells. Traditionally, this systemic enhancement has been achieved through two methods: passive and active immunotherapy.
Understanding Passive and Active Immunotherapy
Passive immunotherapy involves directly targeting cancerous tissues using immune system components, such as antibodies and genetically engineered T cells. Conversely, active immunotherapy aims to enhance the immune system’s activation by adjusting regulatory immune mechanisms. This includes employing agents that stimulate the activity and proliferation of immune response cells, alongside cancer prevention vaccines.
Limitations of Current Enhancement Strategies
Both passive and active immunotherapy strategies fail to address underlying deficiencies in anti-tumor immune responses; instead, they circumvent these issues. The researchers at Yale, in their article published in Cell, compare this method to increasing pressure in a partially obstructed pipe rather than removing the blockage to ensure normal flow. Just as elevated water pressure can lead to damage, enhancement therapies often result in toxic side effects, coupled with low rates of objective antitumor responses across various tumor types.
Normalization Therapies: A New Approach
Overview of Normalization Therapies
In the last decade, significant progress has been made in a distinct approach known as normalization therapies. These therapies focus on specific molecular pathways responsible for deficiencies in the antitumor response, effectively restoring it to normal levels. Continuing with the plumbing analogy, normalization therapies resemble the act of removing a blockage to restore proper water flow.
Targeting the PD Pathway
The initial mechanisms targeted by normalization therapies involve the programmed cell death (PD) pathway. Anti-PD therapies work by preventing the suppression of T cells, thereby returning the immune response to baseline levels. This approach has been associated with higher rates of objective antitumor responses and fewer adverse effects.
Potential of the B7-H1/PD-1 Pathway
The researchers have identified the B7-H1/PD-1 pathway as a potential master switch that can significantly alter tumor environments depending on whether it is activated or suppressed. Inhibiting this pathway has shown promise in resetting and normalizing the immune response around malignant tumors, with notable reductions in tumor size observed during phase 1 clinical trials.
Future Directions in Cancer Immunotherapy
The authors advocate for further investigation into normalization therapies as a critical step in developing more effective and less toxic cancer treatments. They express hope that this innovative approach will establish a new standard in cancer immunotherapy.
Written by Agustin Dominguez Iino, BSc
Reference: Sanmamed MF1, Chen L2. A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization. Cell. 2018 Oct 4;175(2):313-326. doi: 10.1016/j.cell.2018.09.035.